J’avoue et c’est le cas de le dire | John Benjamins

Résumé Cet article décrit le fonctionnement de deux opérateurs discursifs, l’un formé sur dire (c’est le cas de le dire) et l’autre sur le verbe performatif avouer (j’avoue). Nous en fournissons une description syntactico-sémantique et nous examinons les éventuelles raisons de blocage de l’apparition de l’un à la place de l’autre selon les contraintes suivantes : affaiblissement de l’acte de l’aveu, exigence d’une polarité négative, d’un haut degré et/ou d’une situation exemplaire. Ces éléments pris en compte, nous faisons ressortir les spécificités des deux opérateurs soumis à l’étude.

Sci-Net

Videogame localisation, spelling errors and player reception | John Benjamins

Abstract Positioned against the backdrop of the booming videogame industry, the study sheds light on the relationship between player experience and localisation. The experimental manipulation involved spelling errors serving as a proxy to examine how much reception is reshaped by specific characteristics of the target version. The findings indicate that deficient spelling has no traceable effect on player cognitive load, enjoyment or comprehension. From a complementary perspective, while the author of the target version with typos is deemed less diligent than the one in the typo-free condition, they are not perceived as less experienced or less likely to be considered to be a professional translator. On the other hand, spelling errors result in lower translation quality estimations. The discussion is supplemented by results on typo identification and related to findings from film reception.

A roadmap for affordable genetic medicines - Nature

Nineteen genetic therapies have been approved by the U.S. Food and Drug Administration (FDA) to date, a number that now includes the first CRISPR genome editing therapy for sickle cell disease, CASGEVY (exagamglogene autotemcel). This extraordinary milestone is widely celebrated because of the promise for future genome editing treatments of previously intractable genetic disorders and cancers. At the same time, such genetic therapies are the most expensive drugs on the market, with list prices exceeding $4 million per patient. Although all approved cell and gene therapies trace their origins to academic or government research institutions, reliance on for-profit pharmaceutical companies for subsequent development and commercialization results in prices that prioritize recouping investments, paying for candidate product failures, and meeting investor and shareholder expectations. To increase affordability and access, sustainable discovery-to-market alternatives are needed that address system-wide deficiencies. Here, we present recommendations of a multi-disciplinary task force assembled to chart such a path. We describe a pricing structure that, once implemented, could reduce per-patient cost tenfold and propose a business model that distributes responsibilities while leveraging diverse funding sources. We also outline how academic licensing provisions, manufacturing innovation and supportive regulations can reduce cost and enable broader patient treatment.